Overview
ANVS market data
Price History
ANVS price chart
Valuation & Profitability
No Valuation Data Yet
Alpha Vantage and Twelve Data both returned no valuation metrics for ANVS. Check back after the next daily valuation refresh — this symbol may be new, delisted, or temporarily unavailable from both providers.
Company news
8-K filing — Annovis Bio, Inc. (ANVS)SEC EDGAR · Jul 10, 2026, 1:06 AM
Annovis Bio Announces Full Enrollment Of Its Phase 3 Trial Of Buntanetap In Patients With Early Alzheimer’s Disease; The Trial Enrolled 850 Patients; Symptomatic Data Readout Expected In Q1 2027, and Disease-Modifying Data Readout Anticipated in Q1 2028Benzinga · Jul 7, 2026, 11:25 AM
Annovis Bio Announces It Has Regained NYSE Listing ComplianceBenzinga · May 26, 2026, 12:06 PM
Annovis Bio Prices Underwritten Public Offering Of 7,895,000 Shares And Warrants To Purchase Up To 7,105,500 Shares At $1.90 Per UnitBenzinga · May 20, 2026, 12:10 PM
Annovis Bio Announces Launch Of Proposed $250M Public Stock Offering Initially Filed February 12, 2024Benzinga · May 19, 2026, 8:20 PM
Annovis Bio Q1 EPS $(0.63) Misses $(0.40) EstimateBenzinga · May 15, 2026, 11:45 AM